T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
The Bancorp
TBBK
$2.82B
| $9.15M | ﹤0.01% |
468,998
+1,044
| +0.2% | +$22.4K |
|
1327
Pentair
PNR
$10.7B
| $9.13M | ﹤0.01% |
199,395
-19,930
| -9% | -$998K |
|
|
OSH
1328
DELISTED
Oak Street Health, Inc.
OSH
| $9.11M | ﹤0.01% |
554,244
-37,731
| -6% | -$733K |
|
1329
Marqeta
MQ
$1.71B
| $9.11M | ﹤0.01% |
280,699
+14,984
| +6% | +$589K |
|
1330
Carnival Corporation Ltd
CCL
$38.9B
| $9.04M | ﹤0.01% |
1,045,338
-95,012
| -8% | -$1.39M |
|
1331
Enanta Pharmaceuticals
ENTA
$391M
| $8.9M | ﹤0.01% |
188,343
-4,716
| -2% | -$256K |
|
1332
uniQure
QURE
$3.26B
| $8.87M | ﹤0.01% |
475,917
+145,600
| +44% | +$2.32M |
|
1333
CareDx
CDNA
$2.45B
| $8.77M | ﹤0.01% |
408,445
-323,737
| -44% | -$8.98M |
|
1334
Brunswick
BC
$5.29B
| $8.67M | ﹤0.01% |
132,608
-651,619
| -83% | -$47.9M |
|
1335
SoFi Technologies
SOFI
$23.8B
| $8.65M | ﹤0.01% |
1,642,347
-27,623,883
| -94% | -$187M |
|
1336
RingCentral
RNG
$5.66B
| $8.61M | ﹤0.01% |
164,711
-12,593
| -7% | -$956K |
|
|
SPLK
1337
DELISTED
Splunk Inc
SPLK
| $8.54M | ﹤0.01% |
96,501
+1,301
| +1% | +$143K |
|
1338
Ubiquiti
UI
$35.3B
| $8.42M | ﹤0.01% |
33,935
-31,122
| -48% | -$8.28M |
|
1339
Silicon Laboratories
SLAB
$7.28B
| $8.23M | ﹤0.01% |
58,682
-1,677
| -3% | -$235K |
|
1340
ThredUp
TDUP
$416M
| $8.21M | ﹤0.01% |
3,284,475
+1,904,679
| +138% | +$10.3M |
|
1341
Genmab
GMAB
$19.3B
| $8.19M | ﹤0.01% |
252,198
-1,235,837
| -83% | -$40M |
|
1342
Ferguson
FERG
$48B
| $8.13M | ﹤0.01% |
73,405
+32,125
| +78% | +$3.89M |
|
1343
EQT Corp
EQT
$33.8B
| $8.1M | ﹤0.01% |
235,414
-6,042,520
| -96% | -$249M |
|
1344
RB Global
RBA
$16B
| $8.04M | ﹤0.01% |
123,658
-350
| -0.3% | -$20.5K |
|
1345
Palantir
PLTR
$430B
| $8.04M | ﹤0.01% |
886,594
+47,028
| +6% | +$465K |
|
1346
W.P. Carey
WPC
$16.3B
| $7.98M | ﹤0.01% |
98,320
+5,500
| +6% | +$444K |
|
1347
Advanced Drainage Systems
WMS
$11.3B
| $7.85M | ﹤0.01% |
87,200
+67,826
| +350% | +$6.97M |
|
1348
Berkshire Hathaway Class A
BRK.A
$1.09T
| $7.77M | ﹤0.01% |
19
| – | – |
|
|
CCXI
1349
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.68M | ﹤0.01% |
310,129
-55,505
| -15% | -$1.22M |
|
1350
Vistra
VST
$49.1B
| $7.67M | ﹤0.01% |
335,697
-2,546,866
| -88% | -$62.9M |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.